Compare NetApp Inc. (NTAP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Viatris Inc — how do they compare? NetApp Inc. trades at $231.78 (market cap $45.38B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: NetApp Inc. is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Viatris Inc for 57 Days on average.
| NTAP | VTRS | |
|---|---|---|
Market Cap | $45.38B | $20.03B |
Volume | 2,264,311 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $235.84 | $18.27 |
52-Week Low | $94.11 | $9.74 |
Typical Hold Time | 57 Days | 57 Days |
Enterprise Value | $44.34B | $32.15B |
Dividend Yield | 0.9% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $235.84, up 3.23% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support near $233 and resistance at $239. Fundamentals are robust with a 70.63% gross margin and 19.19% net income margin, though valuation multiples like the 33.3 P/E are elevated. Recent news highlights strategic AI partnerships and product launches, including Novus storage for AI infrastructure, driving positive sentiment.
Outlook is positive given earnings momentum and AI-driven growth, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed with a $219.30 price target below current levels, suggesting caution despite bullish technicals. Institutional ownership trends and cash flow improvements support stability, but investors should weigh growth prospects against premium pricing.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
